(DRUG) Bright Minds Biosciences - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: CA10919W1086
DRUG: Seizure, Pain, Depression, Anxiety, PTSD, Epilepsy
Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company based in New York, specializes in developing innovative therapeutics targeting severe and life-altering diseases. Their focus is on selective 5-HT receptor agonists, which are crucial in neurological functions, offering potential treatments for epilepsy, pain, and neuropsychiatry. Their pipeline includes compounds like BMB-101, which has completed Phase 1 trials for seizure disorders, addressing an area with significant unmet medical needs.
The company collaborates with esteemed institutions such as the National Institutes of Health, the University of Texas Medical Branch, and the Medical College of Wisconsin, enhancing their research capabilities. Founded in 2017, Bright Minds Biosciences is listed on NASDAQ under the ticker symbol DRUG, reflecting their commitment to advancing neurological treatments.
3-Month Forecast: - Technical Outlook: DRUG is trading above its SMA200 ($19.09), indicating a bullish trend. However, low average volume (62,889 shares) suggests liquidity risks. The ATR of 3.23 signals moderate volatility, with potential price fluctuations between $34 and $40. - Fundamental Risks: With a high P/B ratio (5.86), the market reflects confidence in growth potential. However, the absence of profitability (P/E: 0.00) and revenue (P/S: 0.00) underscores dependency on clinical success. Negative RoE (-1.83) aligns with typical biotech startup dynamics, emphasizing the need for milestones. - Target Price: Technical indicators suggest a target range of $34 to $40, contingent on trial outcomes and market sentiment.Additional Sources for DRUG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
DRUG Stock Overview
| Market Cap in USD | 226m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2021-03-22 |
DRUG Stock Ratings
| Growth 5y | 12.4% |
| Fundamental | -32.1% |
| Dividend | 0.0% |
| Rel. Strength Industry | 2879 |
| Analysts | - |
| Fair Price Momentum | 31.18 USD |
| Fair Price DCF | - |
DRUG Dividends
No Dividends PaidDRUG Growth Ratios
| Growth Correlation 3m | -38.9% |
| Growth Correlation 12m | 65.9% |
| Growth Correlation 5y | -43.3% |
| CAGR 5y | 7.32% |
| CAGR/Max DD 5y | 0.07 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | 929.91 |
| Beta | 9.99 |
| Volatility | 146.41% |
| Current Volume | 30.4k |
| Average Volume 20d | 48.3k |
As of March 16, 2025, the stock is trading at USD 35.78 with a total of 30,380 shares traded.
Over the past week, the price has changed by +3.71%, over one month by -14.40%, over three months by -7.83% and over the past year by +2652.31%.
Probably not. Based on ValueRay Fundamental Analyses, Bright Minds Biosciences (NASDAQ:DRUG) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -32.06 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DRUG as of March 2025 is 31.18. This means that DRUG is currently overvalued and has a potential downside of -12.86%.
Bright Minds Biosciences has no consensus analysts rating.
According to ValueRays Forecast Model, DRUG Bright Minds Biosciences will be worth about 37.4 in March 2026. The stock is currently trading at 35.78. This means that the stock has a potential upside of +4.58%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 92.3 | 158% |
| Analysts Target Price | 4.9 | -86.4% |
| ValueRay Target Price | 37.4 | 4.6% |